Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
Amy BodyRachel WongJeremy ShapiroAzim JalaliSue-Anne McLachlanSumitra AnandaLara LiptonPrasad CoorayPeter GibbsBelinda LeeMargaret LeePublished in: Internal medicine journal (2020)
A substantial proportion of patients with mPDAC still do not receive active treatment, which may in part by explained by age, poor performance status and comorbidity. Gemcitabine-nab-paclitaxel was the preferred first line chemotherapy regimen. Median OS for treated patients in this cohort was comparable to that of recent published clinical trials. This article is protected by copyright. All rights reserved.
Keyphrases
- clinical trial
- locally advanced
- end stage renal disease
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- chronic kidney disease
- small cell lung cancer
- peritoneal dialysis
- prognostic factors
- metabolic syndrome
- randomized controlled trial
- systematic review
- radiation therapy
- rectal cancer
- advanced non small cell lung cancer
- combination therapy
- skeletal muscle
- insulin resistance